| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A general process for the development of peptide-based immunoassays for monoclonal antibodies
|
Sanchez, Ana B.
|
|
2010
|
66 |
5 |
p. 919-925
|
artikel
|
| 2 |
Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis
|
Li, Chuan-gang
|
|
2010
|
66 |
5 |
p. 981-986
|
artikel
|
| 3 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer
|
Shiozawa, Manabu
|
|
2010
|
66 |
5 |
p. 987-992
|
artikel
|
| 4 |
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
|
Moore, M. M.
|
|
2010
|
66 |
5 |
p. 845-850
|
artikel
|
| 5 |
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
|
Sabharwal, A.
|
|
2009
|
66 |
5 |
p. 829-835
|
artikel
|
| 6 |
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
|
Sehouli, Jalid
|
|
2010
|
66 |
5 |
p. 861-868
|
artikel
|
| 7 |
C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro
|
Yu, Teng
|
|
2010
|
66 |
5 |
p. 999-1003
|
artikel
|
| 8 |
Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine
|
Iwasaki, Hironori
|
|
2010
|
66 |
5 |
p. 953-959
|
artikel
|
| 9 |
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice
|
Letari, Ornella
|
|
2009
|
66 |
5 |
p. 819-827
|
artikel
|
| 10 |
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression
|
Jain, Dilip
|
|
2010
|
66 |
5 |
p. 945-952
|
artikel
|
| 11 |
Increased anticoagulant activity of warfarin used in combination with doxifluridine
|
Nakajima, Masaru
|
|
2010
|
66 |
5 |
p. 969-972
|
artikel
|
| 12 |
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
|
Chan, Jennifer A.
|
|
2010
|
66 |
5 |
p. 961-968
|
artikel
|
| 13 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
|
Yanagihara, Kazuhiro
|
|
2010
|
66 |
5 |
p. 913-918
|
artikel
|
| 14 |
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer
|
Kwon, Jung Hye
|
|
2010
|
66 |
5 |
p. 889-897
|
artikel
|
| 15 |
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
|
Fujisaka, Yasuhito
|
|
2010
|
66 |
5 |
p. 935-943
|
artikel
|
| 16 |
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
|
Morgan, Robert J.
|
|
2010
|
66 |
5 |
p. 927-933
|
artikel
|
| 17 |
Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients
|
Formelli, Franca
|
|
2010
|
66 |
5 |
p. 993-998
|
artikel
|
| 18 |
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α
|
Chintala, Sreenivasulu
|
|
2010
|
66 |
5 |
p. 899-911
|
artikel
|
| 19 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
|
Prete, Salvatore Del
|
|
2009
|
66 |
5 |
p. 837-844
|
artikel
|
| 20 |
Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action
|
Zhang, Yi
|
|
2010
|
66 |
5 |
p. 851-859
|
artikel
|
| 21 |
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
|
Ackler, Scott
|
|
2010
|
66 |
5 |
p. 869-880
|
artikel
|
| 22 |
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
|
Choi, Brian S.
|
|
2010
|
66 |
5 |
p. 973-980
|
artikel
|
| 23 |
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
|
Scatena, Caroline D.
|
|
2010
|
66 |
5 |
p. 881-888
|
artikel
|
| 24 |
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
|
Scatena, Caroline D.
|
|
|
66 |
5 |
p. 881-888
|
artikel
|
Tijdschrift beschrijving